Glaukos Completes Patient Enrollment for GLK-321 Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Clinical Trial Progress: Glaukos has completed patient enrollment of 275 individuals for the GLK-321 clinical trial targeting Demodex blepharitis, marking a significant milestone for the iLution drug platform and potentially enhancing the company's position in the ophthalmic treatment market.
- Innovative Drug Platform: GLK-321 employs the proprietary iLution platform to enable dropless transdermal delivery of medication, aiming to improve patient compliance and reduce side effects associated with traditional eye drop regimens, thereby enhancing patients' quality of life.
- Market Opportunity: Demodex blepharitis is a common yet significantly underdiagnosed chronic eyelid disease, and as awareness and diagnosis improve, Glaukos anticipates a surge in treatment demand from millions of potential patients, further expanding its market share.
- Trial Design: The Phase 2 trial is a randomized, double-masked, placebo-controlled study primarily assessing the efficacy of GLK-321 in eliminating blepharitis symptoms after six weeks of treatment, with successful outcomes laying the groundwork for future commercialization.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GKOS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GKOS
Wall Street analysts forecast GKOS stock price to fall
13 Analyst Rating
12 Buy
0 Hold
1 Sell
Strong Buy
Current: 134.650
Low
72.00
Averages
127.08
High
165.00
Current: 134.650
Low
72.00
Averages
127.08
High
165.00
About GKOS
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Glaukos Completes Patient Enrollment for GLK-321 Clinical Trial
- Clinical Trial Progress: Glaukos has completed patient enrollment of 275 individuals for the GLK-321 clinical trial targeting Demodex blepharitis, marking a significant milestone for the iLution drug platform and potentially enhancing the company's position in the ophthalmic treatment market.
- Innovative Drug Platform: GLK-321 employs the proprietary iLution platform to enable dropless transdermal delivery of medication, aiming to improve patient compliance and reduce side effects associated with traditional eye drop regimens, thereby enhancing patients' quality of life.
- Market Opportunity: Demodex blepharitis is a common yet significantly underdiagnosed chronic eyelid disease, and as awareness and diagnosis improve, Glaukos anticipates a surge in treatment demand from millions of potential patients, further expanding its market share.
- Trial Design: The Phase 2 trial is a randomized, double-masked, placebo-controlled study primarily assessing the efficacy of GLK-321 in eliminating blepharitis symptoms after six weeks of treatment, with successful outcomes laying the groundwork for future commercialization.
See More
Glaukos Reports Record Q1 2026 Earnings and Raises Guidance
- Record Sales Performance: Glaukos reported a record net sales of $150.6 million in Q1 2026, reflecting a 41% year-over-year increase, indicating strong market performance that is likely to drive stock price appreciation.
- iDose TR Sales Surge: The U.S. glaucoma franchise achieved net sales of $93.5 million, up 58% year-over-year, with iDose TR contributing approximately $54 million, showcasing the company's success in new product adoption and enhancing competitive positioning.
- Epioxa Commercialization Progress: Epioxa, an incision-free alternative for corneal cross-linking, has been launched across areas serving about 65% of the U.S. population, with plans to expand to approximately 95%, significantly increasing market penetration and revenue potential.
- Margin Improvement: The first quarter saw an 84% gross margin, up 120 basis points from last year, with management maintaining a full-year margin guidance of 84% to 86%, indicating a positive outlook for cost control and profitability.
See More
Glaukos (GKOS) Q1 2026 Earnings Transcript
See More
Glaukos Q1 Earnings Announcement Scheduled
- Earnings Announcement Schedule: Glaukos (GKOS) is set to announce its Q1 earnings on April 29th after market close, with a consensus EPS estimate of -$0.28, reflecting a 27.3% year-over-year decline, indicating challenges in profitability.
- Revenue Growth Expectations: The anticipated revenue for Q1 is $137 million, representing a 28.4% year-over-year increase, showcasing strong growth potential driven by new product launches.
- Performance Estimate Revisions: Over the past three months, EPS estimates have seen two upward revisions and ten downward revisions, while revenue estimates have experienced eight upward revisions and one downward revision, indicating market uncertainty regarding the company's future performance.
- Historical Performance Review: Over the last two years, Glaukos has beaten EPS estimates 50% of the time and has achieved a 100% success rate in exceeding revenue estimates, demonstrating stability in revenue and market confidence.
See More
Glaukos Corporation Schedules Q1 2026 Earnings Call and Webcast
- Earnings Release Schedule: Glaukos Corporation plans to release its Q1 2026 financial results after market close on April 29, 2026, with management discussing the results during a conference call and webcast at 1:30 PM PT (4:30 PM ET), providing insights into the company's financial performance and future outlook.
- Participation Details: Investors can join the conference call by dialing 800-715-9871 (U.S.) or 646-307-1963 (International) and entering Conference ID 1333241, with a replay available post-call for those unable to attend live, ensuring accessibility to key financial discussions.
- Innovative Product Launch: Since launching its first Micro-Invasive Glaucoma Surgery (MIGS) device in 2012, Glaukos has continued to innovate in the treatment of glaucoma, corneal disorders, and retinal diseases, with the 2024 launch of iDose®TR offering continuous 24/7 glaucoma drug therapy, representing a significant advancement in treatment options.
- Market Positioning and Development: As the sole developer of the FDA-approved corneal cross-linking therapy, Glaukos is committed to improving treatment outcomes for keratoconus patients through its proprietary bio-activated pharmaceutical, showcasing the company's leadership in ophthalmic medical technology.
See More
Epioxa™ HD: First Incision-Free Drug Therapy for Keratoconus Approved by FDA
- Innovative Drug Launch: Glaukos announces the commercial availability of Epioxa™ HD as the first FDA-approved incision-free therapy for keratoconus, representing a significant breakthrough in treatment standards that is expected to greatly enhance patient experience and recovery times.
- Patient Support Programs: The company plans to increase investments in patient awareness, education, and access, launching multiple support initiatives including a co-pay assistance program and a patient assistance program aimed at addressing the longstanding issues of underdiagnosis and undertreatment in the keratoconus patient community.
- Significant Clinical Outcomes: Epioxa reduces pain associated with traditional epithelial removal through its enriched oxygen and light mechanism, providing a more comfortable treatment experience while ensuring clinically meaningful outcomes, delivering exceptional value to patients and the healthcare system.
- Substantial Market Potential: With the launch of Epioxa, Glaukos anticipates attracting more attention from keratoconus patients, increasing market share, and driving continued growth in the ophthalmic treatment sector through innovative technologies.
See More
Glaukos Completes Patient Enrollment for GLK-321 Clinical Trial
- Clinical Trial Progress: Glaukos has completed patient enrollment of 275 individuals for the GLK-321 clinical trial targeting Demodex blepharitis, marking a significant milestone for the iLution drug platform and potentially enhancing the company's position in the ophthalmic treatment market.
- Innovative Drug Platform: GLK-321 employs the proprietary iLution platform to enable dropless transdermal delivery of medication, aiming to improve patient compliance and reduce side effects associated with traditional eye drop regimens, thereby enhancing patients' quality of life.
- Market Opportunity: Demodex blepharitis is a common yet significantly underdiagnosed chronic eyelid disease, and as awareness and diagnosis improve, Glaukos anticipates a surge in treatment demand from millions of potential patients, further expanding its market share.
- Trial Design: The Phase 2 trial is a randomized, double-masked, placebo-controlled study primarily assessing the efficacy of GLK-321 in eliminating blepharitis symptoms after six weeks of treatment, with successful outcomes laying the groundwork for future commercialization.
See More
Glaukos Reports Record Q1 2026 Earnings and Raises Guidance
- Record Sales Performance: Glaukos reported a record net sales of $150.6 million in Q1 2026, reflecting a 41% year-over-year increase, indicating strong market performance that is likely to drive stock price appreciation.
- iDose TR Sales Surge: The U.S. glaucoma franchise achieved net sales of $93.5 million, up 58% year-over-year, with iDose TR contributing approximately $54 million, showcasing the company's success in new product adoption and enhancing competitive positioning.
- Epioxa Commercialization Progress: Epioxa, an incision-free alternative for corneal cross-linking, has been launched across areas serving about 65% of the U.S. population, with plans to expand to approximately 95%, significantly increasing market penetration and revenue potential.
- Margin Improvement: The first quarter saw an 84% gross margin, up 120 basis points from last year, with management maintaining a full-year margin guidance of 84% to 86%, indicating a positive outlook for cost control and profitability.
See More
Glaukos (GKOS) Q1 2026 Earnings Transcript
See More
Glaukos Q1 Earnings Announcement Scheduled
- Earnings Announcement Schedule: Glaukos (GKOS) is set to announce its Q1 earnings on April 29th after market close, with a consensus EPS estimate of -$0.28, reflecting a 27.3% year-over-year decline, indicating challenges in profitability.
- Revenue Growth Expectations: The anticipated revenue for Q1 is $137 million, representing a 28.4% year-over-year increase, showcasing strong growth potential driven by new product launches.
- Performance Estimate Revisions: Over the past three months, EPS estimates have seen two upward revisions and ten downward revisions, while revenue estimates have experienced eight upward revisions and one downward revision, indicating market uncertainty regarding the company's future performance.
- Historical Performance Review: Over the last two years, Glaukos has beaten EPS estimates 50% of the time and has achieved a 100% success rate in exceeding revenue estimates, demonstrating stability in revenue and market confidence.
See More
Glaukos Corporation Schedules Q1 2026 Earnings Call and Webcast
- Earnings Release Schedule: Glaukos Corporation plans to release its Q1 2026 financial results after market close on April 29, 2026, with management discussing the results during a conference call and webcast at 1:30 PM PT (4:30 PM ET), providing insights into the company's financial performance and future outlook.
- Participation Details: Investors can join the conference call by dialing 800-715-9871 (U.S.) or 646-307-1963 (International) and entering Conference ID 1333241, with a replay available post-call for those unable to attend live, ensuring accessibility to key financial discussions.
- Innovative Product Launch: Since launching its first Micro-Invasive Glaucoma Surgery (MIGS) device in 2012, Glaukos has continued to innovate in the treatment of glaucoma, corneal disorders, and retinal diseases, with the 2024 launch of iDose®TR offering continuous 24/7 glaucoma drug therapy, representing a significant advancement in treatment options.
- Market Positioning and Development: As the sole developer of the FDA-approved corneal cross-linking therapy, Glaukos is committed to improving treatment outcomes for keratoconus patients through its proprietary bio-activated pharmaceutical, showcasing the company's leadership in ophthalmic medical technology.
See More
Epioxa™ HD: First Incision-Free Drug Therapy for Keratoconus Approved by FDA
- Innovative Drug Launch: Glaukos announces the commercial availability of Epioxa™ HD as the first FDA-approved incision-free therapy for keratoconus, representing a significant breakthrough in treatment standards that is expected to greatly enhance patient experience and recovery times.
- Patient Support Programs: The company plans to increase investments in patient awareness, education, and access, launching multiple support initiatives including a co-pay assistance program and a patient assistance program aimed at addressing the longstanding issues of underdiagnosis and undertreatment in the keratoconus patient community.
- Significant Clinical Outcomes: Epioxa reduces pain associated with traditional epithelial removal through its enriched oxygen and light mechanism, providing a more comfortable treatment experience while ensuring clinically meaningful outcomes, delivering exceptional value to patients and the healthcare system.
- Substantial Market Potential: With the launch of Epioxa, Glaukos anticipates attracting more attention from keratoconus patients, increasing market share, and driving continued growth in the ophthalmic treatment sector through innovative technologies.
See More
